Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TEN-K vs HEMICLOR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium chloride is a potassium supplement that replaces potassium ions in the body, essential for maintaining intracellular osmotic pressure, acid-base balance, and nerve conduction. It acts as a cofactor for numerous enzymes and is critical for myocardial and skeletal muscle contraction.
Hemichlor (HEMICLOR) is a brand name for a combination product containing chlorpheniramine and pseudoephedrine. Chlorpheniramine is a first-generation antihistamine that antagonizes histamine at H1 receptor sites, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.
Treatment and prevention of hypokalemia,Hypokalemia associated with diuretic therapy,Hypokalemia in patients with digitalis toxicity
Relief of symptoms associated with seasonal and perennial allergic rhinitis, including nasal congestion, sneezing, rhinorrhea, and pruritus,Off-label: Adjunctive treatment for acute sinusitis and common cold symptoms
10 m Eq (one tablet) orally once daily or as directed by physician.
50-100 mg intravenously every 6 hours or 100 mg orally every 12 hours.
Terminal elimination half-life is approximately 30-60 minutes; clinical context: short half-life necessitates frequent dosing for maintenance of potassium levels.
Terminal elimination half-life 18–24 hours in normal renal function; prolonged to 36–48 hours in moderate renal impairment (Cr Cl 30–50 m L/min); adjust dosing interval in renal disease.
Potassium chloride is not metabolized; it is absorbed and excreted primarily by the kidneys. Approximately 90% is eliminated in urine, with the remainder in feces and sweat.
Chlorpheniramine is extensively metabolized in the liver via CYP450 enzymes, primarily CYP2D6, and excreted renally as metabolites. Pseudoephedrine is partially metabolized in the liver by N-demethylation and excreted largely unchanged in urine; its metabolism is not significantly enzyme-dependent.
Renal: >90% excreted unchanged by the kidneys; fecal: <5%
Primarily renal (85–90% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal < 5%.
Minimal (<10%); not significantly bound to plasma proteins.
70–80% (primarily to albumin).
Approximately 0.2-0.4 L/kg; reflects distribution primarily in extracellular fluid.
0.3–0.5 L/kg (indicates moderate tissue distribution).
Oral: 100% (potassium chloride is well absorbed); IV: 100%.
Oral: 40–60% (due to first-pass metabolism; food may reduce absorption).
Contraindicated in severe renal impairment (GFR <30 m L/min). For GFR 30-60 m L/min, reduce dose by 50% and monitor serum potassium. Use with caution in mild impairment.
GFR 30-50 m L/min: 50 mg IV every 12h or 50 mg PO every 24h; GFR 10-29 m L/min: 50 mg IV every 24h or 25 mg PO every 24h; GFR <10 m L/min: 25 mg IV every 48h or avoid use.
No specific adjustment; however, use with caution in severe hepatic impairment due to risk of hyperkalemia.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Not established; safety and efficacy in pediatric patients not determined.
5-10 mg/kg IV every 6h, max 100 mg/dose.
Start at 5 m Eq orally daily; titrate slowly and monitor serum potassium due to age-related renal function decline.
Start at lower end of dosing range (50 mg IV every 12h or 50 mg PO every 24h) due to reduced renal function and increased sensitivity.
None
No FDA black box warning is present for HEMICLOR.
Hyperkalemia risk, especially in patients with renal impairment,Cardiac effects: risk of arrhythmias with rapid correction or high doses,Gastrointestinal reactions: ulceration, bleeding, perforation with solid oral formulations,Use with caution in patients with renal insufficiency, adrenal insufficiency, diabetes, or cardiac disease,Monitor serum potassium levels and ECG during therapy
Cardiovascular effects: Use with caution in patients with hypertension, ischemic heart disease, or arrhythmias,CNS depression: Chlorpheniramine may cause sedation; avoid concurrent use with alcohol or other CNS depressants,Monoamine oxidase inhibitor (MAOI) interaction: Concomitant use with MAOIs or within 14 days of discontinuation can precipitate hypertensive crisis,Urinary retention: Use cautiously in patients with prostatic hypertrophy or bladder neck obstruction,Photosensitivity: Chlorpheniramine may increase risk of photosensitivity reactions
Hyperkalemia,Severe renal impairment with oliguria or anuria,Untreated Addison's disease,Solid oral potassium supplements in patients with delayed gastrointestinal transit
Hypersensitivity to chlorpheniramine, pseudoephedrine, or any component,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI therapy,Severe hypertension or severe coronary artery disease,Narrow-angle glaucoma,Urinary retention,Breastfeeding (relative contraindication due to pseudoephedrine excretion)
Avoid high-potassium foods (bananas, oranges, spinach, potatoes, tomatoes) in large amounts; limit salt substitutes containing potassium chloride. Take with food to minimize GI irritation.
Avoid alcohol and grapefruit juice. Take with food to reduce gastrointestinal upset. Limit caffeine intake as it may worsen anxiety or gastrointestinal symptoms.
No known teratogenic effects based on available data. Potassium supplementation does not increase risk of congenital anomalies above baseline. However, avoid hyperkalemia in pregnant women as high potassium levels may pose risks. First trimester: No evidence of fetal harm. Second trimester: Monitor maternal potassium levels. Third trimester: Adjusted potassium requirements may occur due to increased renal clearance; maintain normokalemia.
Hemichlor (hydrochlorothiazide) is contraindicated in pregnancy due to risk of fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances. First trimester: associated with neural tube defects in animal studies and possible oligohydramnios. Second/third trimester: risk of fetal bradycardia, hyponatremia, hypokalemia, and decreased placental perfusion.
Potassium is excreted into breast milk in amounts not likely to cause adverse effects in nursing infants. The M/P ratio is approximately 0.4. Supplementation at physiological doses is considered compatible with breastfeeding. Monitor maternal serum potassium to avoid excessive dosage.
Hydrochlorothiazide is excreted in breast milk in low concentrations. M/P ratio approximately 0.04-0.06. No adverse effects reported in infants, but may suppress lactation at high doses. Use with caution, monitor infant for electrolyte disturbances.
No specific dose adjustment required for TEN-K based on pregnancy alone. However, pregnancy can increase renal clearance of potassium, potentially lowering serum levels. Monitor potassium levels and adjust dose if hypokalemia develops. Typical dose range: 20-100 m Eq/day, titrated according to serum potassium. Avoid excessive dosing to prevent hyperkalemia.
Pregnancy increases volume of distribution and renal clearance of hydrochlorothiazide, potentially reducing peak serum concentration. However, due to fetal risks, thiazide diuretics are generally avoided in pregnancy. If essential, use lowest effective dose and monitor maternal/fetal status closely. No specific dose adjustment studies exist.
TEN-K is a high-dose potassium chloride formulation (10 m Eq per tablet) used for hypokalemia. Do not split or crush tablets; they are extended-release to prevent GI irritation. Monitor serum potassium and renal function; avoid in severe renal impairment or hyperkalemia. Consider potential for esophageal ulceration if tablet lodges.
HEMICLOR contains clidinium bromide (quaternary ammonium anticholinergic) and chlordiazepoxide (benzodiazepine). Monitor for anticholinergic side effects (dry mouth, blurred vision, urinary retention, constipation). Avoid use in patients with narrow-angle glaucoma, obstructive uropathy, or myasthenia gravis. Chlordiazepoxide may cause dependence; limit duration to 4-8 weeks. Use with caution in elderly due to increased sensitivity to anticholinergic effects and risk of falls.
Take with a full glass of water and with food or after a meal to reduce stomach upset.,Swallow tablets whole; do not crush, chew, or split them.,Avoid salt substitutes or potassium-containing supplements unless directed by your doctor.,Report signs of hyperkalemia: muscle weakness, irregular heartbeat, tingling in hands/feet.,Store at room temperature, away from moisture and heat.
Take exactly as prescribed; do not increase dose or stop abruptly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Avoid alcohol and other CNS depressants.,Report any signs of urinary retention, severe constipation, or blurred vision.,Do not share with others; risk of dependence.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TEN-K vs HEMICLOR, answered by our medical review team.
TEN-K is a Electrolyte supplement that works by Potassium chloride is a potassium supplement that replaces potassium ions in the body, essential for maintaining intracellular osmotic pressure, acid-base balance, and nerve conduction. It acts as a cofactor for numerous enzymes and is critical for myocardial and skeletal muscle contraction.. HEMICLOR is a Electrolyte Supplement that works by Hemichlor (HEMICLOR) is a brand name for a combination product containing chlorpheniramine and pseudoephedrine. Chlorpheniramine is a first-generation antihistamine that antagonizes histamine at H1 receptor sites, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TEN-K and HEMICLOR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TEN-K is: 10 m Eq (one tablet) orally once daily or as directed by physician.. The standard adult dose of HEMICLOR is: 50-100 mg intravenously every 6 hours or 100 mg orally every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TEN-K and HEMICLOR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TEN-K is classified as Category C. No known teratogenic effects based on available data. Potassium supplementation does not increase risk of congenital anomalies above baseline. However, avoid hyperkalemia in pregna. HEMICLOR is classified as Category C. Hemichlor (hydrochlorothiazide) is contraindicated in pregnancy due to risk of fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances. First trimester: associated . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.